Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Artelo Shares Jump On Favorable Preclinical Data In Cancer-Related Muscle-Wasting Syndrome

  • Artelo Biosciences Inc (NASDAQ: ARTL) says its ART27.13 shows promising preclinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia) via a CB2 mediated mechanism of action.
  • ART27.13 is a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia. 
  • "These exciting early results demonstrate that ART27.13 can reduce negative effects of chemicals produced by multiple cancers on human muscle fibers," added Saoirse O'Sullivan, Ph.D., Vice President Translational Science, Artelo Biosciences. 
  • "We look forward to seeing how these results may translate into the ongoing CAReS study currently in the final stages of enrolling cohort 3 at six clinical trial sites in the United Kingdom and Ireland."
  • Cachexia is a multi-organ and often irreversible muscle-wasting syndrome associated with cancer and other serious chronic illnesses. 
  • Price Action: ARTL shares are up 37.70% at $0.58 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.